cagrisema novo nordisk news

Novo Nordisk's next-gen obesity drug Cagrisema

Novo Nordisk defends next-gen obesity drug CagriSema, gives details of new trial

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed investors and wiped $125 billion from its market value.

Fortune on MSN · 3h

As growth slows, CFO says Novo Nordisk is prepping for the next generation of weight loss drugs

Novo Nordisk’s multibillion-dollar honeymoon phase spearheaded by Ozempic and Wegovy is ending. Now the Danish drugmaker is hunting for new patients to maintain its crown as Europe’s most valuable company.

Benzinga.com · 2h

Novo Nordisk Q4 Earnings: Wegovy Sales More Than Double, Seeks Regulatory Approval For Hybrid Weight Loss Drug In 2026

Novo Nordisk reported Q4 sales of $11.96 billion, beating estimates. The company plans a new phase 3 trial for CagriSema in 2025, with results expected in Q1.

Wegovy sales double to boost Novo Nordisk's fourth quarter but slower growth predicted

Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the final quarter of ...

devdiscourse3h

Challenges and Confidence: Novo Nordisk's CagriSema Trial and Market Response

Novo Nordisk's CEO reassures that side-effects are not an issue in the trial of CagriSema, their next-generation obesity drug. Despite weaker-than-expected trial results, the company is optimistic ...

43m

NVO CLASS ACTION: BFA Law Alerts Novo Nordisk Investors of the Imminent March 25 Class Action Deadline

New York, New York-- (Newsfile Corp. - February 5, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Novo Nordisk (NYSE: NVO) and certain ...

Novo Nordisk's sales increased by 25% in Danish kroner and by 26% at constant exchange rates to DKK 290.4 billion in 2024

Financial report for the period 1 January 2024 to 31 December 2024 Operating profit increased by 25% in Danish kroner and by ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results